NO810024L - Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater. - Google Patents

Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater.

Info

Publication number
NO810024L
NO810024L NO810024A NO810024A NO810024L NO 810024 L NO810024 L NO 810024L NO 810024 A NO810024 A NO 810024A NO 810024 A NO810024 A NO 810024A NO 810024 L NO810024 L NO 810024L
Authority
NO
Norway
Prior art keywords
group
het
alk
formula
ring
Prior art date
Application number
NO810024A
Other languages
English (en)
Norwegian (no)
Inventor
Mikkel Josef Gacek
Kjell Undheim
Original Assignee
Nyegaard & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyegaard & Co As filed Critical Nyegaard & Co As
Publication of NO810024L publication Critical patent/NO810024L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
NO810024A 1980-01-07 1981-01-06 Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater. NO810024L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8000381 1980-01-07

Publications (1)

Publication Number Publication Date
NO810024L true NO810024L (no) 1981-07-08

Family

ID=10510470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO810024A NO810024L (no) 1980-01-07 1981-01-06 Fremgangsmaate for fremstilling av farmasoeytisk aktive pyrimidinonderivater.

Country Status (13)

Country Link
US (1) US4399140A (da)
EP (1) EP0032131B1 (da)
JP (1) JPS56150087A (da)
AT (1) ATE4715T1 (da)
AU (1) AU543939B2 (da)
CA (1) CA1168239A (da)
DE (1) DE3160886D1 (da)
DK (1) DK149892B (da)
ES (2) ES498337A0 (da)
IE (1) IE50765B1 (da)
NO (1) NO810024L (da)
NZ (1) NZ195947A (da)
ZA (1) ZA8164B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1160226A (en) * 1980-07-15 1984-01-10 Gordon H. Phillipps Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor
NZ197715A (en) * 1980-07-15 1984-12-14 Glaxo Group Ltd Substituted pyrimin-2-ones and pharmaceutical compositions
US4596870A (en) * 1981-01-09 1986-06-24 Nyegaard & Co. A.S. Substituted pyrimidin-2-ones and the salts thereof
EP0087326B1 (en) * 1982-02-24 1987-05-13 Nycomed As Substituted pyrimidin-2-ones and the salts thereof
SU1235864A1 (ru) * 1983-03-11 1986-06-07 Отделение ордена Ленина института химической физики АН СССР Нитроксильные производные 5-фторурацила,обладающие противоопухолевой активностью
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
US20160002204A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, The University Of Texas System Gls1 inhibitors for treating disease
PL3164394T3 (pl) 2014-07-03 2020-09-07 Board Of Regents, The University Of Texas System Inhibitory GLS1 do leczenia chorób
CN107921044B (zh) 2015-06-30 2022-01-21 德州大学系统董事会 用于治疗疾病的gls1抑制剂
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (r)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-n-메틸-1h-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833586A (en) * 1971-03-25 1974-09-03 Morton Norwich Products Inc 1-(substituted benzyl)-2-(1h)pyrimidones and 1-(substituted benzyl)tetrahydro-2-(1h)pyrimidones
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
US4003900A (en) * 1976-03-11 1977-01-18 Morton-Norwich Products, Inc. 1-Benzyl-5-chloro-2-(1H)-pyrimidone
US4052399A (en) * 1976-09-13 1977-10-04 Morton-Norwich Products, Inc. 1-[2-(Hexahydro-1H-azepino)ethyl]-2(1H)pyrimidone dihydrochloride
US4052400A (en) * 1976-10-29 1977-10-04 Morton-Norwich Products, Inc. Hypertensive 1-substituted 2(1h)-pyrimidones

Also Published As

Publication number Publication date
AU543939B2 (en) 1985-05-09
ES509219A0 (es) 1983-03-16
NZ195947A (en) 1983-09-02
US4399140A (en) 1983-08-16
EP0032131B1 (en) 1983-09-21
IE810013L (en) 1981-07-07
ATE4715T1 (de) 1983-10-15
DK3281A (da) 1981-07-08
JPS56150087A (en) 1981-11-20
CA1168239A (en) 1984-05-29
ES8304946A1 (es) 1983-03-16
AU6601681A (en) 1981-07-16
ES8205399A1 (es) 1982-06-01
IE50765B1 (en) 1986-07-09
ZA8164B (en) 1982-03-31
ES498337A0 (es) 1982-06-01
EP0032131A1 (en) 1981-07-15
DE3160886D1 (en) 1983-10-27
DK149892B (da) 1986-10-20

Similar Documents

Publication Publication Date Title
AU2004228352B2 (en) Aminopyrimidine derivatives and their medical use
JP5624762B2 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
ES2240449T3 (es) Moduladores receptores de adenosina.
EP1675861B1 (en) Pyrimidothiophene compounds
CN110028491B (zh) 纤维母细胞生长因子受体抑制剂
CN105143206B (zh) 用于治疗癌症的嘧啶-2,4-二胺衍生物
CA2589328A1 (en) Multicyclic bis-amide mmp inhibitors
US20120309739A1 (en) Akt / pkb inhibitors
AU2004215428A1 (en) Aminoheteroaryl compounds as protein kinase inhibitors
AU2008252380A1 (en) Quinazolin-oxime derivatives as Hsp90 inhibitors
KR20130122778A (ko) FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체
CA2899646A1 (en) Substituted xanthines and methods of use thereof
SG184766A1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
UA113077C2 (xx) 6-алкілпіридини як міметики smac
El‐Mekabaty et al. Convenient synthesis of novel sulfonamide derivatives as promising anticancer agents
IE83508B1 (en) Quinoxalines, processes for their preparation, and their use
CN115702150A (zh) Cd73抑制剂及其在医药上的应用
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
EP0032131B1 (en) 5-halo-pyrimidin-2-ones, the salts thereof, processes for their preparation and pharmaceutical compositions containing them
Strekowski et al. Synthesis of 2‐chloro‐4, 6‐di (heteroaryl) pyrimidines
DK156722B (da) Analogifremgangsmaade til fremstilling af 2-piperazinopyrimidinderivater
AU2007334039B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer
AU2007334040A1 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
TW201910330A (zh) 磺醯胺類衍生物、其製備方法及其在醫藥上的用途
US4650800A (en) Substituted pyrimidin-2-ones, the salts thereof, pharmaceutical compositions containing them and a method therefor